BACKGROUND: Although the DASH (Dietary Approaches to Stop Hypertension) diet has been shown to lower blood pressure (BP) in short-term feeding studies, it has not been shown to lower BP among free-living individuals, nor has it been shown to alter cardiovascular biomarkers of risk. OBJECTIVE: To compare the DASH diet alone or combined with a weight management program with usual diet controls among participants with prehypertension or stage 1 hypertension (systolic BP, 130-159 mm Hg; or diastolic BP, 85-99 mm Hg). DESIGN AND SETTING: Randomized, controlled trial in a tertiary care medical center with assessments at baseline and 4 months. Enrollment began October 29, 2003, and ended July 28, 2008. PARTICIPANTS: Overweight or obese, unmedicated outpatients with high BP (N = 144). INTERVENTIONS:Usual diet controls, DASH diet alone, and DASH diet plus weight management. OUTCOME MEASURES: The main outcome measure is BP measured in the clinic and by ambulatory BP monitoring. Secondary outcomes included pulse wave velocity, flow-mediated dilation of the brachial artery, baroreflex sensitivity, and left ventricular mass. RESULTS:Clinic-measured BP was reduced by 16.1/9.9 mm Hg (DASH plus weight management); 11.2/7.5 mm (DASH alone); and 3.4/3.8 mm (usual diet controls) (P < .001). A similar pattern was observed for ambulatory BP (P < .05). Greater improvement was noted for DASH plus weight management compared with DASH alone for pulse wave velocity, baroreflex sensitivity, and left ventricular mass (all P < .05). CONCLUSION: For overweight or obese persons with above-normal BP, the addition of exercise and weight loss to the DASH diet resulted in even larger BP reductions, greater improvements in vascular and autonomic function, and reduced left ventricular mass. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00571844.
RCT Entities:
BACKGROUND: Although the DASH (Dietary Approaches to Stop Hypertension) diet has been shown to lower blood pressure (BP) in short-term feeding studies, it has not been shown to lower BP among free-living individuals, nor has it been shown to alter cardiovascular biomarkers of risk. OBJECTIVE: To compare the DASH diet alone or combined with a weight management program with usual diet controls among participants with prehypertension or stage 1 hypertension (systolic BP, 130-159 mm Hg; or diastolic BP, 85-99 mm Hg). DESIGN AND SETTING: Randomized, controlled trial in a tertiary care medical center with assessments at baseline and 4 months. Enrollment began October 29, 2003, and ended July 28, 2008. PARTICIPANTS: Overweight or obese, unmedicated outpatients with high BP (N = 144). INTERVENTIONS: Usual diet controls, DASH diet alone, and DASH diet plus weight management. OUTCOME MEASURES: The main outcome measure is BP measured in the clinic and by ambulatory BP monitoring. Secondary outcomes included pulse wave velocity, flow-mediated dilation of the brachial artery, baroreflex sensitivity, and left ventricular mass. RESULTS: Clinic-measured BP was reduced by 16.1/9.9 mm Hg (DASH plus weight management); 11.2/7.5 mm (DASH alone); and 3.4/3.8 mm (usual diet controls) (P < .001). A similar pattern was observed for ambulatory BP (P < .05). Greater improvement was noted for DASH plus weight management compared with DASH alone for pulse wave velocity, baroreflex sensitivity, and left ventricular mass (all P < .05). CONCLUSION: For overweight or obesepersons with above-normal BP, the addition of exercise and weight loss to the DASH diet resulted in even larger BP reductions, greater improvements in vascular and autonomic function, and reduced left ventricular mass. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00571844.
Authors: Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder Journal: Am J Med Date: 2003-07 Impact factor: 4.965
Authors: Lawrence J Appel; Catherine M Champagne; David W Harsha; Lawton S Cooper; Eva Obarzanek; Patricia J Elmer; Victor J Stevens; William M Vollmer; Pao-Hwa Lin; Laura P Svetkey; Sarah W Stedman; Deborah R Young Journal: JAMA Date: 2003 Apr 23-30 Impact factor: 56.272
Authors: D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield Journal: Lancet Date: 1992-11-07 Impact factor: 79.321
Authors: G de Simone; S R Daniels; R B Devereux; R A Meyer; M J Roman; O de Divitiis; M H Alderman Journal: J Am Coll Cardiol Date: 1992-11-01 Impact factor: 24.094
Authors: Jirar Topouchian; Ramzi El Feghali; Bruno Pannier; Shuyu Wang; Feng Zhao; Karel Smetana; Koon Teo; Roland Asmar Journal: Vasc Health Risk Manag Date: 2007
Authors: Andrew Sherwood; Faye S Routledge; William K Wohlgemuth; Alan L Hinderliter; Cynthia M Kuhn; James A Blumenthal Journal: Am J Hypertens Date: 2011-06-02 Impact factor: 2.689
Authors: Lysanne Goyer; Robert Dufour; Caroline Janelle; Chantal Blais; Christine L'Abbé; Emilie Raymond; Jacques de Champlain; Pierre Larochelle Journal: J Behav Med Date: 2012-03-09
Authors: Rhoda N Ndanuko; Linda C Tapsell; Karen E Charlton; Elizabeth P Neale; Marijka J Batterham Journal: Adv Nutr Date: 2016-01-15 Impact factor: 8.701
Authors: Allan R K Sales; Bruno M Silva; Fabricia J Neves; Natália G Rocha; Renata F Medeiros; Renata R T Castro; Antonio C L Nóbrega Journal: Eur J Appl Physiol Date: 2012-01-24 Impact factor: 3.078
Authors: Rachel W Goode; Melissa A Kalarchian; Linda Craighead; Molly B Conroy; John Wallace; Shaun M Eack; Lora E Burke Journal: Eat Behav Date: 2018-03-09